Combination of
Losartan Angiotensin II receptor antagonist
Hydrochlorothiazide Thiazide diuretic
Clinical data
Trade names Anzaplus, Cozaar comp, Hyzaar, Ocsaar Plus
  • US: D (Evidence of risk)
Routes of
ATC code C09DA01 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
PubChem (CID) 24783652
KEGG D07895

Losartan/hydrochlorothiazide is a combination drug used as an antihypertensive, consisting of losartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a diuretic).

The losartan/hydrochlorothiazide combination preparation is marketed by Merck under the trade name Hyzaar and by Xeno Pharmaceuticals under the name Anzaplus. Merck, Sharp & Dohme market it as Ocsaar Plus in Israel. It is marketed as Cozaar comp in Sweden and South Africa.

In 2010, the patent for the combination expired, and a number of pharmaceutical companies promptly filed and received approval to sell the generic losartan, with and without hydrochlorothiazide, in the United States.[1]


The recommended dosage of losartan-hydrochlorothiazide for adults with high blood pressure (hypertension) will vary between losartan-hydrochlorothiazide 50 mg/12.5 mg and losartan-hydrochlorothiazide 100 mg/25 mg once a day. Based on the initial blood pressure response and/or losartan-hydrochlorothiazide side effects, the dosage may be increased or decreased. With each change in dosage, it may take up to a month to see the full effect of losartan-hydrochlorothiazide on lowering blood pressure.


This article is issued from Wikipedia - version of the 9/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.